Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
SANDY, Utah, Jan. 31, 2013 /PRNewswire/ -- Rafarma Pharmaceuticals, Inc. (the "Company") OTC symbol "RAFA" announced that it has been named one of the four national strategic Pharmaceutical Suppliers to the Russian Federation. This important step for the company means it will receive guaranteed government contracts helping load the manufacturing facility to 100% capacity.
The Russian pharmaceutical industry supplies both the national health care system and hospital sector with 70% of medicines in physical volume. The Russian pharmaceutical market is considered to be one of the most dynamic and growing in the world. It continues to grow an average 10-12% per year since 2003 (Source: The Strategy of Development of the Pharmaceutical Industry of the Russian Federation, http://www.osec.ch/de/filefield-private/files/25703/field_blog_public_files/5244).
CEO David Anderson stated, "This is a very exciting time for the Company and we are extremely happy with the ability to be one of the four national strategic Pharmaceutical Suppliers to the Russian Federation."
As previously announced the Company will facilitate investor awareness using social media. Follow Rafarma Pharmaceuticals on Facebook at www.facebook.com/rafarmainfo or Twitter at www.twitter.com/rafarmainfo. You can also text "RAFA" to 74499 to receive updates via text message.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.
SOURCE Rafarma Pharmaceuticals, Inc.